Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
MLO | Ann: mFund - Monthly Redemption Report - MLO02 | 27/09/24 | 0 | 74 | |||
|
|||||||
MLO | Ann: mFund - Distribution - MLO02 | 27/09/24 | 0 | 71 | |||
|
|||||||
MLO | Ann: mFund - Target Market Determination - MLO02 | 12/09/24 | 0 | 82 | |||
|
|||||||
MLO | Ann: mFund - Monthly Redemption Report - MLO02 | 15/08/24 | 0 | 62 | |||
|
|||||||
MLO | Ann: mFund - Distribution - MLO02 | 15/08/24 | 0 | 71 | |||
|
|||||||
MLO | Ann: mFund - Monthly Redemption Report - MLO02 | 23/07/24 | 0 | 66 | |||
|
|||||||
MLO | Ann: mFund - Net Asset Value - MLO02 | 23/07/24 | 0 | 66 | |||
|
|||||||
MLO | Ann: mFund - Distribution - MLO02 | 23/07/24 | 0 | 74 | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |